SEC Form 4 · accession 0000899243-17-015190
CytoDyn Inc. · CYDY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anthony Caracciolo
Officer — Executive Chairman · Director
Period of report
May 31, 2017
Accepted (ET)
Jun 2, 2017 · 6:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001175680
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Convertible Promissory NoteF3,F1,F2 | $0.75 | May 31, 2017 | A | — | A | May 31, 2017 | Jan 31, 2018 | Common Stock | 1,333,333 | — | I |
| WarrantsF3,F1 | $1.35 | May 31, 2017 | A | 333,333 | A | May 31, 2017 | May 31, 2022 | Common Stock | 333,333 | 333,333 | I |
Explanation of responses
- F1Subject to adjustment in the event of certain stock split or reverse stock split recapitalizations.
- F2Does not include additional shares issuable upon conversion of accrued interest.
- F3As part of a private offering to accredited investors, the reporting person purchased from the issuer for a combined price of $1.0 million (i) a $1.0 million convertible promissory note, bearing interest at 7.0% annually, which is convertible into shares of the issuer's common stock at an initial conversion price of $0.75 per share, and (ii) a warrant covering 25% of the number of shares underlying the convertible promissory note.